These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36966205)

  • 21. The Relationship Between Development Start Lag and Approval Lag in Oncology Drug Development in Japan.
    Nakajima K; Dagher R; Strawn L; Urushidani J; Kurokawa T; Chiba K
    Ther Innov Regul Sci; 2015 Nov; 49(6):911-919. PubMed ID: 30222391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lag Time for New Innovative, First-in-Class, Drug Approval in Japan.
    Miyazaki T; Komiyama M; Matsumaru N; Maeda H; Tsukamoto K
    Biol Pharm Bull; 2022; 45(4):477-482. PubMed ID: 35370272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Impact of Regulatory Reforms in China on Drug Lag: The Role of Clinical Development Strategies.
    Han Y; Jiang R; Li J; Wang Y; Shao R; Xie J
    Clin Pharmacol Ther; 2024 Jun; 115(6):1400-1407. PubMed ID: 38429944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Co-Development of Oncology Drugs and Companion Diagnostics: Analyses of Approval Lags and Drug Development Periods in Recently Approved Cases in Japan.
    Tanaka A; Suzuki H; Toyoshima S; Nagai N
    Ther Innov Regul Sci; 2022 Jan; 56(1):85-95. PubMed ID: 34406635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulatory review time for approval of oncology drugs in Japan between 2001 and 2014. Considerations of changes, factors that affect review time, and difference with the United States.
    Maeda H; Kurokawa T
    J Clin Pharmacol; 2015 May; 55(5):481-9. PubMed ID: 25560978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative Assessment of Drug Lag for Approved Oncology Targeted Therapies Between Saudi Arabia, the United States, and the European Union.
    Alnuhait M; Alshammari A; Alharbi M; AlOtaibi L; Alharbi R; Khobrani A; Alkhudair N; Alshamrani M; Alrajhi AM
    Ther Innov Regul Sci; 2024 Jul; 58(4):678-686. PubMed ID: 38536660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Delays in clinical development of neurological drugs in Japan].
    Ikeda M
    Rinsho Shinkeigaku; 2017 Jun; 57(6):274-279. PubMed ID: 28552868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Approval of new biopharmaceuticals 1999-2006: comparison of the US, EU and Japan situations.
    Tsuji K; Tsutani K
    Eur J Pharm Biopharm; 2008 Mar; 68(3):496-502. PubMed ID: 17884403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug approval delays in hematologic malignancies between Europe and the US and between Japan and the US: a clinical perspective.
    Matsuda K; Nagai S; Sugimoto K
    Jpn J Clin Oncol; 2023 Dec; 53(12):1125-1129. PubMed ID: 37642224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent trends and success factors in reducing the lag time to approval of new drugs in Japan.
    Honig PK
    Clin Pharmacol Ther; 2014 May; 95(5):467-9. PubMed ID: 24747231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significant differences in drug lag in clinical development among various strategies used for regulatory submissions in Japan.
    Ueno T; Asahina Y; Tanaka A; Yamada H; Nakamura M; Uyama Y
    Clin Pharmacol Ther; 2014 May; 95(5):533-41. PubMed ID: 24213186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of Drug Characteristics for Implementing Multiregional Clinical Trials Including Japan.
    Rokuda M; Matsumaru N; Tsukamoto K
    Clin Ther; 2018 Feb; 40(2):284-295. PubMed ID: 29361305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of expedited programs in the United States, as foreign regulatory factors, on clinical development time in Japan.
    Tajima G; Matsumaru N; Tsukamoto K
    J Clin Pharm Ther; 2022 Sep; 47(9):1395-1401. PubMed ID: 35488803
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An evaluation of drug lag for new drugs approved by the Indian regulator relative to the United States, European Union, and Japanese regulatory agencies: A 15-year analysis (2004-2018).
    Konwar M; Maurya MR; Nishandar TB; Thatte UM; Gogtay NJ
    Perspect Clin Res; 2021; 12(3):159-164. PubMed ID: 34386381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characteristics of drugs approved in Japan without conducting confirmatory clinical trials.
    Izuka S; Matsumaru N; Tsukamoto K
    J Clin Pharm Ther; 2021 Dec; 46(6):1582-1590. PubMed ID: 34250620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of Expedited Programs in the United States on Oncology Drug Development in Japan.
    Tanaka M; Matsumaru N; Tsukamoto K
    Ther Innov Regul Sci; 2019 Mar; 53(2):199-206. PubMed ID: 29732928
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Delays in new drug applications in Japan and industrial R&D strategies.
    Hirai Y; Kinoshita H; Kusama M; Yasuda K; Sugiyama Y; Ono S
    Clin Pharmacol Ther; 2010 Feb; 87(2):212-8. PubMed ID: 19940847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical trial designs to obtain marketing authorization of drugs for haematological malignancy in Japan, the EU and the US.
    Nagai S; Ozawa K
    Br J Haematol; 2016 Jul; 174(2):249-54. PubMed ID: 27018163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Development and Regulatory Pathways of Monoclonal Antibodies in Japan.
    Liao H; Li Z
    Ther Innov Regul Sci; 2022 Mar; 56(2):173-183. PubMed ID: 34825323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between drug lag and factors associated with clinical trials in Japan.
    Ohwaki K; Nakabayashi T
    J Clin Pharm Ther; 2014 Dec; 39(6):649-52. PubMed ID: 25200123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.